COMP <GO>
ABBV vs UNH // RETURN ON INVESTED CAPITAL (ROIC)
AbbVie Inc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ABBV 8
— UNH 5
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
roic
11.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABBV VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABBV | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 70.20% | 88.57% | -18.37 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 29.00% | 11.47% | +17.53 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.3x | 16.4x | +16.85 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 3.47% | 6.48% | -3.01 | UNH | /fcf-yield <GO> |
| Operating Margin | 24.60% | 4.82% | +19.78 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 6.90% | 3.14% | +3.76 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | 6.46% | +2.14 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.27% | 2.28% | -0.01 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.33 | 3.12 | +2.21 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.1 | 59.2 | +5.90 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.33 | +0.82 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 113.1x | 17.1x | +96.01 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $513.86B | $368.83B | $145.03B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABBV REV | UNH REV | ABBV GROSS % | UNH GROSS % | ABBV FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.16B | $447.57B | 70.2% | 88.7% | $17.82B | $16.07B |
| FY 2024 | $56.33B | $400.28B | 70.0% | 88.3% | $17.83B | $20.70B |
| FY 2023 | $54.32B | $371.62B | — | 89.6% | $20.39B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABBV // BETA 1.15
UNH // BETA 0.33